Promimic (PRO) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
22 Aug, 2025Executive summary
Four new customer agreements signed in Q2, a record for a single quarter, with six new agreements in H1 2025.
Net sales for Q2 were 11.3 MSEK, down 6% year-over-year, but currency-adjusted sales grew 3%.
Core business (licenses and royalties) grew 21% (33% currency-adjusted) in Q2.
EBITDA turned positive at 69 TSEK in Q2, compared to -997 TSEK last year.
Strategic collaborations expanded, including new agreements with Lincotek and Curiteva.
Financial highlights
Q2 net sales: 11.3 MSEK (12.0 MSEK last year); total operating income: 13.7 MSEK (12.9 MSEK).
Q2 operating result: -1.3 MSEK (-2.3 MSEK); net result after tax: -1.5 MSEK (-2.5 MSEK).
H1 net sales: 20.0 MSEK (20.7 MSEK); total operating income: 24.7 MSEK (22.3 MSEK).
H1 operating result: -4.9 MSEK (-6.0 MSEK); net result after tax: -6.0 MSEK (-6.0 MSEK).
Cash flow for Q2: -5.2 MSEK (-8.6 MSEK); cash at period end: 28.4 MSEK (38.0 MSEK).
Outlook and guidance
Updated long-term targets: CAGR >25% and EBITDA margin >40%.
Focus on returning to growth with a target of four new agreements per year.
No specific forecasts provided, but guidance for strong growth and margin improvement.
Latest events from Promimic
- 2025 saw modest sales growth, reduced losses, and record new customer agreements.PRO
Q4 202524 Feb 2026 - Record sales growth and new FDA approvals drive future expansion and strong outlook.PRO
Q3 202519 Nov 2025 - Sales up 6% in Q3, with record product approvals and strong royalty growth.PRO
Q3 202413 Jun 2025 - Record sales and robust growth, with new clinical approvals fueling future expansion.PRO
Q2 202413 Jun 2025 - Q1 2025 saw sales growth, new strategic deals, and improved cash flow despite a net loss.PRO
Q1 20256 Jun 2025 - Record sales and clinical milestones achieved, with robust growth outlook for 2025.PRO
Q4 20245 Jun 2025